Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies

SD Zondor, PJ Medina - Annals of Pharmacotherapy, 2004 - journals.sagepub.com
OBJECTIVE: To review the pharmacology, pharmacokinetics, and pivotal clinical trials for
bevacizumab, emphasizing its use in colorectal cancer. DATA SOURCES: A …
被引用次数：184 相关文章

Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies.

SD Zondor, PJ Medina - The Annals of Pharmacotherapy, 2004 - europepmc.org
Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. -
Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu About …
[PDF] psu.edu

[PDF][PDF] Bevacizumab: An Angiogenesis Inhibitor with Efficacy in Colorectal and Other Malignancies

SD Zondor, PJ Medina - The Annals of Pharmacotherapy, 2004 - Citeseer
OBJECTIVE: To review the pharmacology, pharmacokinetics, and pivotal clinical trials for
bevacizumab, emphasizing its use in colorectal cancer. DATA SOURCES: A …

Bevacizumab: An Angiogenesis Inhibitor with Efficacy in Colorectal and Other Malignancies

SD Zondor, PJ Medina - Annals of Pharmacotherapy, 2004 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> OBJECTIVE:</jats: title>< jats: p> To review the pharmacology,
pharmacokinetics, and pivotal clinical trials for bevacizumab, emphasizing its use in …

Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies

SD Zondor, PJ Medina - The Annals of pharmacotherapy, 2004 - pubmed.ncbi.nlm.nih.gov
Objective To review the pharmacology, pharmacokinetics, and pivotal clinical trials for
bevacizumab, emphasizing its use in colorectal cancer. Data sources A PubMed/MEDLINE …

[引用][C] Bevacizumab: An angiogenesis inhibitor with efficacy in colorectal and other malignancies

SD ZONDOR, PJ MEDINA - The Annals of pharmacotherapy, 2004 - Whitney